# RMC-9805-001: HCP commentary report

> 71 verified statements (7 from clinicians verified by NPI or staff page) from 26 commentary sources · 8 findings · updated Oct 29, 2026

## Report

- Trial: Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
- NCT ID: NCT06040541
- Registry: https://clinicaltrials.gov/study/NCT06040541
- Sponsor: Revolution Medicines, Inc.
- Phase: Phase 1
- Status: Recruiting
- Indications: Non-small cell lung cancer, Colorectal cancer, Advanced solid tumors
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: f7ae32e1fef84799723178547d433434c7cf90ddb4d0f96b7de4408459501015

## Counts

- HCP commentary sources screened: 51
- Sources cited by verified statements: 26
- Verified statements: 71
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 7
- Findings: 8
- People found in screened sources: 17
- Voices cited: 17
- Cited voices identity-verified: 12
- Organisational or shared accounts (not counted as people): 5

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on RMC-9805-001 in the sources reviewed for this edition leads to one open question: What evidence would justify choosing dual blockade rather than chemotherapy or single-agent RAS inhibition, for which patients and with which tolerability trade-offs? Its leading findings: (1) A chemotherapy-free PDAC option is an important question, not an established treatment conclusion. (2) two speakers welcome the NSCLC findings; the presenter's docetaxel comparison is contextual. (3) favorable tolerability is regimen-specific and does not mean absence of consequential toxicity. 5 more findings follow. 51 sources screened, 26 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What evidence would justify choosing dual blockade rather than chemotherapy or single-agent RAS inhibition, for which patients and with which tolerability trade-offs?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A chemotherapy-free PDAC option is an important question, not an established treatment conclusion
- F2. Two speakers welcome the NSCLC findings; the presenter's docetaxel comparison is contextual
- F3. Favorable tolerability is regimen-specific and does not mean absence of consequential toxicity
- F4. Combination development has a rationale, but early response expectations include explicit skepticism
- F5. Smoking phenotype and treated brain metastases raise applicability questions, not subgroup answers
- F6. Target-validation enthusiasm coexists with careful separation of model, molecular and clinical evidence
- F7. Access and comparative trial choice remain practical questions
- F8. A general PDAC video connects precision-oncology optimism with genomic profiling

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 8 | 7 | 7 | recorded | 3 |
| F2 | 19 | 13 | 6 | 7 | recorded | 4 |
| F3 | 16 | 14 | 8 | 8 | recorded | 4 |
| F4 | 14 | 11 | 6 | 8 | recorded | 5 |
| F5 | 8 | 7 | 1 | 1 | none recorded | 3 |
| F6 | 16 | 19 | 8 | 8 | recorded | 4 |
| F7 | 3 | 3 | 3 | 3 | none recorded | 3 |
| F8 | 2 | 1 | 1 | 0 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 2 | 0 | 0 | 0 | 9 | 0 | 7 posts and articles | yes |
| F2 | 7 | 3 | 0 | 1 | 8 | 20 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F3 | 10 | 1 | 0 | 2 | 3 | 17 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F4 | 10 | 1 | 0 | 1 | 2 | 14 | 1 | 5 posts and articles, 1 podcast or video | yes |
| F5 | 1 | 3 | 0 | 1 | 3 | 8 | 0 | 1 podcast or video | yes |
| F6 | 6 | 2 | 1 | 1 | 6 | 23 | 2 | 7 posts and articles, 1 podcast or video | yes |
| F7 | 1 | 2 | 0 | 0 | 0 | 3 | 0 | 3 posts and articles | yes |
| F8 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 1 podcast or video | yes |

### Trial dimensions

- Primary endpoint: Adverse events: F1 (1 shared claims), F2 (2 shared claims), F3 (4 shared claims), F4 (1 shared claims)
- Primary endpoint: Dose Limiting Toxicities: F1 (2 shared claims), F3 (3 shared claims)
- Secondary endpoints: F3 (1 shared claims), F6 (1 shared claims)
- Population and setting: F2 (3 shared claims), F5 (6 shared claims)
- The comparison: F1 (3 shared claims), F2 (1 shared claims), F3 (2 shared claims), F4 (5 shared claims), F6 (1 shared claims)
- Safety and tolerability: F1 (4 shared claims), F2 (4 shared claims), F3 (10 shared claims), F4 (1 shared claims), F6 (1 shared claims), F7 (1 shared claims)
- Design and conduct: F2 (2 shared claims), F3 (3 shared claims), F4 (2 shared claims), F5 (2 shared claims), F6 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 9 sections | Paid |
| Verified statements with short source quotes and links | 71 | Paid |
| Trial aspects mapped | 13 | Free |
| Sources with links | 26 | Counts free |
| Speaker attribution for cited voices | 17 | Paid |

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Adverse events | discussed | 4 | 3 |
| Primary endpoint: Dose Limiting Toxicities | discussed | 4 | 3 |
| Secondary endpoints | discussed | 2 | 2 |
| Population and setting | discussed | 7 | 1 |
| The comparison | discussed | 10 | 6 |
| Safety and tolerability | discussed | 13 | 9 |
| Design and conduct | discussed | 6 | 2 |
| Could dual blockade become a chemotherapy-free PDAC option? | discussed | 9 | 7 |
| NSCLC durability, unmet need and the docetaxel benchmark | discussed | 12 | 5 |
| CNS activity cannot yet be inferred | discussed | 2 | 1 |
| Target validation, mechanism and preclinical response displays | discussed | 16 | 9 |
| Early confidence, response-rate skepticism and conditional combination rationales | discussed | 8 | 4 |
| Geographic access, trial choice and comparative information needs | discussed | 3 | 3 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 44 | 19 |
| LinkedIn posts | 4 | 4 |
| YouTube | 2 | 2 |
| Bluesky threads | 1 | 1 |

- Screened window: 2023-09-15 to 2026-09-26
- Cited window: 2023-09-15 to 2026-07-06
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG 12D-Mutant Solid Tumors
- Registry: NCT06040541 (https://clinicaltrials.gov/study/NCT06040541)
- Study IDs: RMC-9805-001
- Sponsor: Revolution Medicines, Inc.
- Design: Phase 1 · interventional, non randomized, parallel, phase1
- Status: Recruiting
- Enrollment: 604 (estimated)
- Start: 2023-09-07 (actual)
- Primary completion: 2026-12-31 (estimated)
- Primary endpoint: Adverse events (Up to 3 years)
- Primary endpoint: Dose Limiting Toxicities (21 days)
- Intervention: RMC-9805 (drug)
- Intervention: RMC-6236 (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on mutation-defined eligibility for investigational combination treatments in non-small cell lung cancer.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 44 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The report describes the sources reviewed for this edition, not all HCPs or all public discussion. Some passages were not fully assessed, and many potentially relevant sources without an explicit trial name were not read.
- Unnamed references and transcription variants may be missing. One potentially relevant statement could not be used because its molecular-eligibility wording was unreliable.
- Clinical roles are not established for several named social-media authors. Source descriptions such as MD or PhD are not independent verification of a clinical role, and an organizational relay is not necessarily its author's own clinical view.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Repeated posts, reposts and multiple unidentified turns do not establish independent HCP agreement or consensus.
- Comments on early RMC-9805 work or the same treatment setting that do not name the trial are attributed context, not additional identified results from NCT06040541. A general PDAC video's genomic-profiling recommendation is selection context, not G12D efficacy evidence.
- Early-phase, selected-population and cross-study observations do not establish superiority over chemotherapy, docetaxel or a single RAS inhibitor. Predictions and conditional efficacy thresholds remain predictions and conditions.
- No protocol, matching regulatory label or trial results publication is included. Statements about FDA designation and dose-selection consultation remain attributed presentation remarks.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (71 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (12 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/rmc-9805-001-nct06040541
- Agents: POST https://www.erudio.com/api/orders with {"report": "rmc-9805-001-nct06040541", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=rmc-9805-001-06040541

## Cite

Erudio Health. RMC-9805-001 (NCT06040541): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/rmc-9805-001-nct06040541

## Machine access

- JSON: https://www.erudio.com/reports/rmc-9805-001-nct06040541.json
- Markdown: https://www.erudio.com/reports/rmc-9805-001-nct06040541.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "rmc-9805-001-06040541"}`